Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of holomycin in inhibiting nlrp3 inflammasome activation

A technology of inflammasomes and panmycin, applied in anti-inflammatory agents, digestive system, organic active ingredients, etc., can solve the undiscovered problems of inhibiting inflammasome activation and IL-1β secretion

Active Publication Date: 2020-04-07
ACADEMY OF MILITARY MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Holomycin (Holomycin, referred to as HL in this article) is an antibiotic produced by Streptomyces, which has broad-spectrum antibacterial activity, but it has not been found to inhibit the activation of inflammasome and the secretion of IL-1β.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of holomycin in inhibiting nlrp3 inflammasome activation
  • Application of holomycin in inhibiting nlrp3 inflammasome activation
  • Application of holomycin in inhibiting nlrp3 inflammasome activation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] This example is used to illustrate that under the stimulation of different NLRP3-specific agonists, holomycin can significantly inhibit the processing, maturation and release of IL-1β or IL-18 after activation of NLRP3 inflammasome.

[0061] ①. Cultivation and differentiation of mouse bone marrow-derived macrophages (BMDM): take about 10 weeks old C57BL / 6 mouse bone marrow cells, and use RPMI 1640 medium + 10% inactivated serum + 100ng / ml MSCF (macrophage Cell colony-stimulating factor, Peprotech) was cultured, and the medium was changed every three days, and mature BMDM could be obtained after culturing for 7 days.

[0062] ②. Inoculate 2.5×10 5 cells / hole into a 24-well plate, RPMI 1640 medium + 10% inactivated serum without MCSF was cultured overnight, then 100ng / mL lipopolysaccharide (LPS, Invivogen Company, tlrl-pb5lps) stimulated BMDM for 6h, and then added different concentrations of Panmycin (HL, 0nM, 5nM, 10nM, 25nM, 50nM, 100nM, 250nM; TRC Company, H458490) w...

Embodiment 2

[0068] This example is used to illustrate that panmycin can inhibit the enzyme activity of Caspase-1 in the NLRP3 inflammasome and the pyroptosis caused by its activation.

[0069] ①. Acquisition of BMDM: Same as step ① in Embodiment 1.

[0070] ②. Inoculate 5×10 6 Cells were cultured overnight in RPMI 1640 medium+10% inactivated serum without MCSF in a 60mm (non-treated) culture dish, then 100ng / mL lipopolysaccharide (LPS, Invivogen, tlrl-pb5lps) stimulated BMDM for 6h, and then added whole Mycin (HL, 100nM; TRC Company, H458490) was treated for 2h, the full mycin was removed, the cells were collected into a sterile flow tube, and the FAM-YVAD-FMK substrate fluorescent probe (ImmunoChemistry Company, FAM-FLICA TM Caspase 1 analysis kit, 97), washed once with PBS, stimulated with 20 μM nizhrinidine for different times (0 min, 15 min, 30 min, 45 min), washed once with PBS, and then detected the fluorescence intensity of substrate binding by flow cytometry. The result is as ...

Embodiment 3

[0074] This example is used to illustrate that panmycin can specifically inhibit the multimerization of ASC during the activation of NLRP3 inflammasome.

[0075] ①. Acquisition of BMDM: Same as step ① in Embodiment 1.

[0076] ②. Place 75% ethanol-sterilized coverslips in a 24-well plate, and then inoculate 5×10 5 Cells / well were cultured overnight in RPMI1640 medium + 10% serum without MCSF, then 100 ng / mL lipopolysaccharide was used to stimulate BMDM for 6 h, then holomycin (HL, 100 nM; TRC company, H458490) was added for 2 h, and holomycin was withdrawn. Add 20μM nizhrinidine to stimulate for 45min, fix the cells with 4% paraformaldehyde, and detect the formation of ASC spots by immunofluorescence. The result is as Figure 7-8 shown. *** p<0.0001.

[0077] During the activation of inflammasomes, the spatial structure of ASC multimerizes and forms spots, which can be observed under confocal laser microscopy by immunofluorescence. Figure 7-8 The results showed that holo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biology and medicine and discloses an application of holomycin in inhibition of the activation of an NLRP3 inflammasome. The holomycin can inhibit NLRP3 protein self-deubiquitination under agonist stimulation, binding of NLRP3 to an ASC protein, formation of ASC spots and activation of Caspase-1, and finally inhibit IL-1 beta and IL-18 secretion. The holomycincan inhibit monosodium urate-induced peritonitis in vivo. Therefore, holomycin can be used a specific drug for treatment on NLRP3 abnormal activation-related diseases.

Description

technical field [0001] The invention relates to the fields of biology and medicine, in particular to the application of holomycin in the preparation for inhibiting the activation of NLRP3 inflammasome, the application of holomycin in inhibiting the deubiquitination of NLRP3 protein, and the application of holomycin in inhibiting NLRP3 and ASC The application of protein binding, the application of holomycin in inhibiting the activation of Caspase-1 protein, the application of holomycin in the inhibition of NLRP3 inflammasome secretion of IL-1β and / or IL-18, the application of holomycin in the use of Application of a drug for preventing and / or treating diseases related to abnormal activation of NLRP3 inflammasomes, a method for inhibiting activation of NLRP3 inflammasomes, a method for preventing and / or treating diseases related to abnormal activation of NLRP3 inflammasomes, and overall Mycin. Background technique [0002] Innate immunity is the body's first line of defense t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/407A61P29/00A61P31/04A61P19/06A61P19/02A61P9/10A61P11/00A61P1/16
CPCA61K31/407A61P1/16A61P9/10A61P11/00A61P19/02A61P19/06A61P29/00A61P31/04
Inventor 尹荣华任广明杨晓明汪煜张洁张文马文兵李长燕于淼葛常辉詹轶群陈慧
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com